BRIEF-TFF Pharmaceuticals Announces Additional Positive Data From Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial

Reuters04-15

April 15 (Reuters) - TFF Pharmaceuticals Inc :

* TFF PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) PHASE 2 TRIAL FOLLOWING ORAL PRESENTATION AT THE ISHLT 44TH ANNUAL LATE BREAKING CLINICAL SCIENCE ABSTRACT SESSIONS

* TFF PHARMACEUTICALS INC: SUCCESSFUL TRANSITION OF EIGHT OF EIGHT PATIENTS FROM ORAL TACROLIMUS TO TFF TAC

* TFF PHARMACEUTICALS INC: NO TFF TAC DISCONTINUATION DUE TO AN AE

* TFF PHARMACEUTICALS INC: PLANS TO OPEN AN IND IN US TO EXPLORE USE OF TFF TAC EARLY POST-TRANSPLANT IN PREPARATION FOR A REGISTRATIONAL TRIAL

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2427619077?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-15 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427619077","market":"us","top_or_hot":-1,"title":"BRIEF-TFF Pharmaceuticals Announces Additional Positive Data From Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial","media":"Reuters","content":"<html><body><p>April 15 (Reuters) - <a href=\"https://laohu8.com/S/TFFP\">TFF Pharmaceuticals</a> Inc   :</p><p>   * TFF PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) PHASE 2 TRIAL FOLLOWING ORAL PRESENTATION AT THE ISHLT 44TH ANNUAL LATE BREAKING CLINICAL SCIENCE ABSTRACT SESSIONS</p><p>   * TFF PHARMACEUTICALS INC: SUCCESSFUL TRANSITION OF EIGHT OF EIGHT PATIENTS FROM ORAL TACROLIMUS TO TFF TAC</p><p>   * TFF PHARMACEUTICALS INC: NO TFF TAC DISCONTINUATION DUE TO AN AE</p><p>   * TFF PHARMACEUTICALS INC: PLANS TO OPEN AN IND IN US TO EXPLORE USE OF TFF TAC EARLY POST-TRANSPLANT IN PREPARATION FOR A REGISTRATIONAL TRIAL</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-TFF Pharmaceuticals Announces Additional Positive Data From Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-TFF Pharmaceuticals Announces Additional Positive Data From Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-15 20:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 15 (Reuters) - TFF Pharmaceuticals Inc   :   * TFF PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) PHASE 2 TRIAL FOLLOWING ORAL PRESENTATION AT...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2427619077","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427619077","pubTimestamp":1713183883,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 15  - TFF Pharmaceuticals Inc   :   * TFF PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM THE TACROLIMUS INHALATION POWDER  PHASE 2 TRIAL FOLLOWING ORAL PRESENTATION AT THE ISHLT 44TH ANNUAL LATE BREAKING CLINICAL SCIENCE ABSTRACT SESSIONS   * TFF PHARMACEUTICALS INC: SUCCESSFUL TRANSITION OF EIGHT OF EIGHT PATIENTS FROM ORAL TACROLIMUS TO TFF TAC   * TFF PHARMACEUTICALS INC: NO TFF TAC DISCONTINUATION DUE TO AN AE   * TFF PHARMACEUTICALS INC: PLANS TO OPEN AN IND IN US TO EXPLORE USE OF TFF TAC EARLY POST-TRANSPLANT IN PREPARATION FOR A REGISTRATIONAL TRIALSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TAC":"Transalta Corp","TFFP":"TFF Pharmaceuticals","BK4105":"独立电力生产商与能源贸易商"},"translate_title":"TFF制药宣布他克莫司吸入粉剂（TFF TAC）2期试验的额外阳性数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAC":1,"TFFP":1},"content_text":"April 15 (Reuters) - TFF Pharmaceuticals Inc   :   * TFF PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM THE TACROLIMUS INHALATION POWDER (TFF TAC) PHASE 2 TRIAL FOLLOWING ORAL PRESENTATION AT THE ISHLT 44TH ANNUAL LATE BREAKING CLINICAL SCIENCE ABSTRACT SESSIONS   * TFF PHARMACEUTICALS INC: SUCCESSFUL TRANSITION OF EIGHT OF EIGHT PATIENTS FROM ORAL TACROLIMUS TO TFF TAC   * TFF PHARMACEUTICALS INC: NO TFF TAC DISCONTINUATION DUE TO AN AE   * TFF PHARMACEUTICALS INC: PLANS TO OPEN AN IND IN US TO EXPLORE USE OF TFF TAC EARLY POST-TRANSPLANT IN PREPARATION FOR A REGISTRATIONAL TRIALSource text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427619077"}